Back to Search Start Over

Factors Associated with Pulmonary Embolism Recurrence and the Benefits of Long-term Anticoagulant Therapy.

Authors :
Anniccherico-Sanchez FJ
Alonso-Martinez JL
Urbieta-Echezarreta MA
Villar-Garcia I
Rojo-Alvaro J
Source :
Cardiovascular & hematological disorders drug targets [Cardiovasc Hematol Disord Drug Targets] 2017; Vol. 17 (3), pp. 205-211.
Publication Year :
2017

Abstract

Background: Venous thromboemboli tend to recur. However, the causative factors underlying pulmonary embolism recurrence are not well defined.<br />Aims: To explore the factors associated with pulmonary embolism recurrence.<br />Patients and Methods: Patients diagnosed with pulmonary emboli between 2004 and 2013 at our institution were enrolled. Duration of anticoagulant therapy, new episodes of venous thromboembolism, and deaths were recorded.<br />Results: Pulmonary embolism was diagnosed in 528 patients (median age: 76 years, interquartile range [IQR]: 16; male: 45%). The median follow-up time was 34 months (IQR: 52). In total, 477 patients completed ≥3 months of anticoagulation therapy. Permanent anticoagulation was indicated in 217 (45%) patients, and therapy was discontinued in 260 (55%) patients. Overall, 79 patients experienced a recurrence (5.6 per patient-year). Recurrence was significantly associated with anticoagulation discontinuation (4% vs. 27% of patients who maintained or discontinued therapy, respectively; P<0.001; 95% confidence interval -0.95, -0.86). The median duration between anticoagulation withdrawal and recurrence was 6.5 months (IQR: 23.25). Factors associated with recurrence were unprovoked pulmonary embolism (odds ratio [OR]: 0.45), a greater degree of pulmonary arterial obstruction (OR: 2.5), a delay in initiation of anticoagulation (OR: 3), and higher plasma D-dimer levels during treatment (OR: 2.3). Survival rates were improved for patients who maintained anticoagulation therapy relative to those who discontinued.<br />Conclusion: Pulmonary embolism has a high recurrence rate. Permanent anticoagulant therapy should be considered for patients with idiopathic pulmonary embolism, a high thrombotic burden, and persistently elevated D-dimer levels during treatment, and for patients where therapy was initially delayed.<br /> (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.)

Details

Language :
English
ISSN :
2212-4063
Volume :
17
Issue :
3
Database :
MEDLINE
Journal :
Cardiovascular & hematological disorders drug targets
Publication Type :
Academic Journal
Accession number :
28925904
Full Text :
https://doi.org/10.2174/1871529X17666170918143459